Advertisement

Psychopharmacology

, Volume 77, Issue 3, pp 205–211 | Cite as

Prevention of the serotonin syndrome in rats by repeated administration of monoamine oxidase inhibitors but not tricyclic antidepressants

  • I. Lucki
  • A. Frazer
Original Investigations

Abstract

The serotonin syndrome, a behavioral response produced by the activation of serotonin receptors, and 3H-serotonin binding were examined after repeated treatment of rats with different types of antidepressant drugs. The serotonin syndrome was produced by the direct-acting serotonin receptor agonists 5-methoxy-N,N-dimethyltryptamine (5-MeDMT) or d-lysergic acid diethylamide (LSD). Repeated, but not acute treatment of rats with monoamine oxidase inhibitors (nialamide, pargyline, and phenelzine) prevented the serotonin syndrome in response to either 5-MeDMT or LSD and also reduced 3H-serotonin binding in the brain stem and spinal cord. Pretreatment of rats with p-chlorophenylalanine blocked the ability of nialamide treatment to inhibit the serotonin syndrome caused by 5-MeDMT. By contrast, neither the serotonin syndrome or 3H-serotonin binding was affected significantly by the repeated administration of tricyclic antidepressants (amitriptyline, desmethyl-imipramine, and chlorimipramine) or iprindole. Repeated monoamine oxidase inhibitor treatments may prevent the serotonin syndrome by causing a reduction of 3H-serotonin receptor binding sites in the brain stem and/or spinal cord.

Key words

Serotonin syndrome Monoamine oxidase inhibitors Tricyclic antidepressants 3H-serotonin binding Depression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aprison MH, Takahashi R, Tachiki K (1978) Hypersensitive serotonergic receptors involved in clinical depression: A theory. In: Aprison MH (ed) Neuropharmacology and behavior. Plenum, New York, pp 25–53Google Scholar
  2. Banerjee SP, Kung LS, Riggi SJ, Chanda SK (1977) Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 268:455–456Google Scholar
  3. Bennett JP Jr, Snyder SH (1976) Serotonin and lysergic acid diethylamide binding in rat brain membranes: Relationship to postsynaptic serotonin receptors. Mol Pharmacol 12:373–389Google Scholar
  4. Deakin JFW, Green AR (1978) The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-Dopa to rats. Br J Pharmacol 64:201–209Google Scholar
  5. De Montigny D, Aghajanian GK (1978) Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202:1303–1305Google Scholar
  6. Frazer A (1981) Antidepressant drugs: Effect on adrenergic responsiveness and monoamine receptors. In: Usdin E, Bunney WE, Davis JM (eds) Neuroreceptors: Basic and clinical aspects. Wiley, New York, pp 85–98Google Scholar
  7. Frazer A, Pandey G, Mendels J, Neeley S, Kane M, Hess ME (1974) The effect of tri-iodothyronine in combination with imipramine on [3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology 13:1131–1140Google Scholar
  8. Friedman E, Dallob A (1979) Enhanced serotonin receptor activity after chronic treatment with imipramine or amitriptyline. Commun Psychopharmacol 3:93–99Google Scholar
  9. Grahame-Smith DG (1971) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18:1053–1066Google Scholar
  10. Jacobs BL (1974) Effect of two dopamine receptor blockers on a serotonin-mediated behavioral syndrome in rats. Eur J Pharmacol 27:363–366Google Scholar
  11. Jacobs BL (1976) An animal behavior model for studying central serotonergic synapses. Life Sci 19:777–786Google Scholar
  12. Jacobs BL, Klemfuss H (1975) Brain stem and spinal cord mediation of a serotonergic behavioral syndrome. Brain Res 100:450–457Google Scholar
  13. Koe BK, Weissman A (1966) p-Chlorophenylalanine: A specific depletor of brain serotonin. J Pharmacol Exp Ther 154:499–516Google Scholar
  14. Leysen JE (1981) Serotonergic receptors in brain tissue: Properties and identification of various 3H-ligand binding sites in vitro. J Physiol (Paris) 77:351–362Google Scholar
  15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275Google Scholar
  16. Mogilnicka E, Klimek V (1979) Mianserin, danitracen and amitriptyline withdrawal increases the behavioral responses of rats to L-5-HTP. J Pharm Pharmacol 31:704–705Google Scholar
  17. Moyer JA, Greenberg LH, Frazer A, Weiss B (1981) Subsensitivity of the beta-adrenergic receptor-linked adenylate cyclase system of rat pineal gland following repeated treatment with desmethylimipramine and nialamide. Mol Pharmacol 19:187–193Google Scholar
  18. Nelson D, Herbert A, Bourgoin S, Glowinski J, Hamon H (1978) Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 14:983–995Google Scholar
  19. Oswald I, Brezinova V, Dunleavy DLF (1972) On the slowness of action of tricyclic antidepressant drugs. Br J Psychiatry 120:673–677Google Scholar
  20. Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple 3H-5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220–226Google Scholar
  21. Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide, and 3H-spiroperidol. Mol Pharmacol 16:687–699Google Scholar
  22. Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88–90Google Scholar
  23. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science 212:828–829Google Scholar
  24. Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. Arch Gen Psychiatry 36:749–760Google Scholar
  25. Resnick O, Kurs DM, Raskin M (1964) LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 3:1207–1214Google Scholar
  26. Robinson DS, Nies A, Ravaris CL, Ives JO, Bartlett D (1978) Clinical pharmacology of phenelzine. Arch Gen Psychiatry 35:629–635Google Scholar
  27. Sai-Halasz A (1963) The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamine. Psychopharmacologia 4:385–388Google Scholar
  28. Savage DD, Frazer A, Mendels J (1979) Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain. Eur J Pharmacol 55: 87–88Google Scholar
  29. Savage DD, Mendels J, Frazer A (1980a) Monoamine oxidase inhibitors and serotonin uptake inhibitors: Differential effects on 3H-serotonin binding sites in rat brain. J Pharmacol Exp Ther 212:259–263Google Scholar
  30. Savage DD, Mendels J, Frazer A (1980b) Decrease in 3H-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists. Neuropharmacology 19:1063–1070Google Scholar
  31. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672Google Scholar
  32. Sloviter RS, Drust EG, Connor JD (1978) Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther 206:339–347Google Scholar
  33. Sloviter RS, Drust EG, Damiano BP, Conner JD (1980) A common mechanism for lysergic acid, indole alkylamine and phenethylamine hallucinogens: Serotonergic mediation of behavioral effects in rats. J Pharmacol Exp Ther 214:231–238Google Scholar
  34. Trulson ME, Eubanks EE, Jacobs BL (1976) Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther 198:23–32Google Scholar
  35. Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257:495–496Google Scholar
  36. Wirz-Justice A, Krauchi K, Lichsteiner M, Feer H (1978) Is it possible to modify serotonin receptor sensitivity? Life Sci 23:1249–1254Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • I. Lucki
    • 1
    • 2
  • A. Frazer
    • 1
    • 2
  1. 1.Neuropsychopharmacology UnitVeterans Administration HospitalPhiladelphiaUSA
  2. 2.Departments of Psychiatry and PharmacologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations